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Ginkgo Biloba extract (GBE) is increasingly used to alleviate symptoms of age related cognitive impairment, with preclinical
evidence pointing to a pro-cholinergic eﬀect. While a number of behavioral studies have reported improvements to working
memory (WM) associated with GBE, electrophysiological studies of GBE have typically been limited to recordings during a resting
state. The current study investigated the chronic eﬀects of GBE on steady state visually evoked potential (SSVEP) topography in
nineteen healthy middle-aged (50-61 year old) male participants whilst completing an object WM task. A randomized double-
blind crossover design was employed in which participants were allocated to receive 14 days GBE and 14 days placebo in random
order. For both groups, SSVEP was recorded from 64 scalp electrode sites during the completion of an object WM task both pre-
and 14 days post-treatment. GBE was found to improve behavioural performance on theWM task. GBE was also found to increase
the SSVEP amplitude at occipital and frontal sites and increase SSVEP latency at left temporal and left frontal sites during the hold
component of the WM task. These SSVEP changes associated with GBE may represent more eﬃcient processing during WM task
completion.
1. Introduction
Ginkgo biloba extract (GBE) from dried leaves of the tree
Ginkgo biloba is increasingly used in Europe (especially
Germany) and the United States of America to alleviate
symptoms associated with age-related cognitive impairment
such as age-related amnesic condition, vascular dementia
and dementia of the Alzheimer’s type [1–6]. Recent studies
appear to indicate that GBE (120–600mg) moderately
enhances a number of cognitive processes in healthy young
individuals as well as those suﬀering from age related
cognitive impairment [7–17].
A number of trials of GBE in the treatment and pre-
vention of Alzheimer’s disease (AD) have also demonstrated
significant improvements to cognition [18]; however, its eﬃ-
cacy is not without contention. A large Americanmulticentre
study by DeKosky and colleagues [19] reported no significant
reduction in the incidence of AD in 3069 participants, with
a median followup of 6.1 years. However, recently released
top line findings from a large-scale European study with
2584 elderly individuals (GuidAge; [20]) revealed significant
delays in conversion to AD in patients treated for at least 4
years with GBE (IPSEN [21]).
A criticism of large-scale studies of GBE in dementia has
been that they show a preference for the measurement of
global rather than specific eﬀects and for this reason leave
unanswered the question of the primary eﬀect of GBE on
cognition [22]. One such cognitive domain that GBE has
shown to improve across a number of studies is Working
Memory (WM) [10, 15, 23, 24]. A previous study from
our laboratory [15] revealed that 30-day administration of
120mg/day GBE in young volunteers resulted in significant
improvements in both digit span backwards and working
memory speed. In a review of 29 randomized clinical
trials examining the cognitive eﬀects of GBE, Kaschel [22]
concluded that asmany as 20.7% ofWM tests in chronic GBE
trials had yielded significant results.
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The mechanism by which GBE achieves improvements
in WM is unclear although it is unlikely to involve a
single process. The active compounds of GBE are primarily
flavonol glycosides (24%) and terpene compounds such
as ginkgolides and bilobalide (6%) with smaller amounts
of proanthocyanidins [25]. The compounds have been
shown to possess potent free radical scavenging and antiox-
idant properties that may play an important role in the
neuroprotective properties of GBE [5, 25, 26]. GBE also
influences a number of neurotransmitter systems that are
considered critical in cognition [26, 27]. In particular, GBE
is thought to enhance cholinergic processes in various
cortical regions [5, 28]. Animal in vitro studies indicate that
GBE increases acetyl-choline (ACh) release in hippocampal
synaptosomes [29]. Animal in vivo studies indicate that GBE
improves performance on behavioural measures of spatial
working memory [30], attenuates the amnesia induced by
scopolamine [31], and increases the density of hippocampal
muscarinic receptors [32].
Modulation of the cholinergic system is known to influ-
ence cognitive processes, especially WM [33]. Increases in
cholinergic transmission are known to enhance WM perfor-
mance [34–37], while reductions in cholinergic transmission
compromise performance on WM tasks [38, 39]. Functional
brain imaging studies have revealed that modulation of the
cholinergic system has diﬀerent eﬀects on specific neural
subsystems mediating WM. In a faces WM task, Physostig-
mine, an acetylcholinesterase inhibitor, improved perfor-
mance. These improvements were associated with increased
cerebral blood flow in the visual cortex and decreased blood
flow at right prefrontal cortex, left temporal cortex, and left
hippocampus/parahippocampal gyrus [34, 35].
There have been a number of studies to investigate the
eﬀects of GBE supplementation on brain activity; however,
the majority of these have only examined the eﬀects of GBE
on EEG frequency during a resting state. Itil and colleagues
[40] reported dose-dependent increases in occipital EEG
alpha band activity during resting eyes closed following
single doses of 40, 120, and 240mg GBE. Amore recent study
by Kennedy and colleagues [41] with participants under the
age of 40 yrs reported that “eyes closed” EEG power in both
theta and beta bands was reduced across frontal regions at 4
hours after a single 360mg dose of GBE. In relation to the
chronic eﬀects of GBE on EEG frequency, Hoﬀerberth [42]
reported a significant reduction in theta waveband activity
associated with 3 months GBE at 240mg/day in elderly
patients with AD. The finding of a decrease in theta power in
conjunction with an increase in alpha power associated with
GBE supplementation is in line with the frequency profile
that has been found to be associated with good cognitive and
memory performance [43].
In addition to the analysis of EEG frequency at rest,
another electrophysiological finding that has been reported
in relation to GBE supplementation is a reduction in
P300 latency. In one such study, Semlitsch and colleagues
[44] reported reductions in P300 latencies following both
a single 120mg dose of GBE as well as following 57
days of GBE at 120mg/day in elderly patients with age-
associated memory impairment. The authors suggested that
the decrease in P300 latency associated with GBE may be a
reflection of shorter stimulus evaluation time. In addition
to electrophysiological studies of the eﬀects of GBE on the
brain, Santos and colleagues [45] utilized single photon
emission computed tomography (SPECT) to examine the
neurophysiological eﬀects of 8 months of 80mg/day GBE
supplementation versus placebo in elderly healthy males.
Santos and colleagues [45] reported that the group receiving
GBE displayed increased cerebral perfusion in several areas
including bilateral frontal, bilateral parietal, right-frontal
parietal, left temporal, and right occipital brain regions.
Similar improvements to cerebral perfusion have also been
reported following GBE treatment for brain circulation
insuﬃciency [46].
In order to better understand the neurophysiology
behind improvements in working memory ability brought
about by GBE, it is pertinent to examine changes in brain
electrical activity whilst completing a WM task which has
previously been shown to be improved after GBE adminis-
tration. In the present study, we sought to examine the eﬀects
of GBE on steady-state visually evoked potential (SSVEP)
topography in healthy middle-aged human subjects, while
they performed an object WM task. Previous studies have
revealed characteristic changes in the 13Hz SSVEP (termed
steady state topography; SST) during a delayed-match-to-
sample objectWM task. Specifically, during the intake or per-
ceptual component, we have previously observed decreased
SSVEP amplitude and decreased SSVEP latency at occipital
sites. During the hold component, we have observed an
SSVEP amplitude increase at occipital and medial prefrontal
sites and decreased SSVEP latency at prefrontal sites [47, 48].
In line with studies ofWM that have utilized functional brain
imaging [49, 50], these latency changes have been interpreted
in terms of increased excitation of occipital cortex during the
intake component and increased prefrontal excitation during
the hold component of the WM task [48]. If GBE eﬀects
are mediated by cholinergic processes and the eﬀects are
similar to those of physostigmine as reported by Furey and
colleagues [34, 35], then it would be expected that the eﬀects
of chronic GBE treatment in an object WM task will be to
increase SSVEP latency (corresponding to reduced excitation
or increased inhibition) at temporal and prefrontal sites. In
relation to the behavioural eﬀects of GBE, we hypothesized
that there would be a significant improvement in both the
speed and accuracy of performance in an object WM task
following chronic GBE treatment.
2. Methods
2.1. Participants. Nineteen right handed individuals (10
males) aged between 50 and 61 years (mean 54.9 ± SD 3.1)
participated in the study. Inclusion criteria for this study
were that the subjects be right handed as determined by the
Edinburgh Handedness Inventory and have normal uncor-
rected vision. Exclusion criteria included past history of head
injury requiring hospitalization, intellectual developmental
disability, neurological or psychiatric illness, epilepsy, and/or
a past or current history of substance abuse. The study
was approved by the Human Research Ethics Committee
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of Swinburne University of Technology, and all participants
provided written informed consent.
2.2. Procedure. A randomized double-blind crossover design
was employed in which participants were randomly allocated
to two groups (Group A or B). Participants in Group A were
administered GBE for 14-day followed by a 14 days washout
period (no tablets). The washout period was then followed
by 14 days of placebo administration. SST recordings were
conducted at baseline (before-GBE), 14 days following GBE
(after-GBE), baseline at the end of the washout period
(before-placebo), and 14 days following placebo treatment
(after-placebo). The GBE and placebo treatment periods
were reversed for Group B. The daily dosage was two
tablets of Blackmore’s Ginkgoforte (2× 40mg) or 2 identical
placebo tablets. Each tablet contained Ginkgo biloba extract
equivalent to 2 g dry leaf and was standardized to contain
10.7mg ginkgo flavonol glycosides and 2.7mg ginkgolides
and bilobalide.
2.2.1. Cognitive Tasks. During each of the four SST recording
sessions, participants performed three cognitive activation
tasks: an object WM task, an abstract shape recognition
task, and the continuous performance task, a task designed
to tap sustained attention. This study reports on the WM
findings, findings on the recognition memory, and attention
activation tasks will be presented elsewhere.
Participants performed an object WM task where each
trial required them to hold one or two irregular polygons
in WM. Irregular polygons were selected to minimize the
chance of participants using verbal strategies in the task
[51]. Each trial was preceded by a 1.5 sec interval where
participants fixated on a cross located at the center on a
blank screen. This was followed by a 1.1 sec interval where the
target, comprising one or two irregular polygons, appeared
on the screen. Immediately following the target, a mask
consisting of a circular annulus of radius 3◦ appeared on the
screen for 0.2 sec. During the subsequent 3.0-second hold
period, the screen was blank except for a small cross in the
centre of the screen that acted as a fixation point. Subjects
were then presented with an irregular object (the probe)
and required to indicate whether the object matched one of
the polygons prior to the hold period. A button push with
the right hand indicated a match, while a nonmatch was
indicated by a left button push. Each trial lasted 12 seconds
and subjects performed 20 trials in a 4-minute block. All
subjects undertook two blocks of the task. Reaction time for
each trial was recorded to an accuracy of 1msec.
Control Task. Participants also performed a control task
identical in structure to the WM task except that the “hold”
interval was reduced from 3.0 sec to 0.25 sec, and the pretrial
blank screen was increased in duration from 1.5 sec to 4.5 sec.
Stimuli. Each of the polygons subtended a horizontal and
vertical angle of approximately 1.0◦ when viewed by the
subjects from a fixed distance of 1.34m. Polygons and circles
had a luminance of 13.0 Cd/m2 against the video monitor
background of 1.2 Cd/m2. All polygons were located on an
imaginary circle of radius 3.0◦ centered on the fixation cross.
The stimulus used to evoke the SSVEP was a 13Hz sinusoidal
flicker subtending a horizontal angle of 160◦ and a vertical
angle of 90◦. The modulation depth of the stimulus when
viewed against the background was 45%. A set of goggles,
which permitted the sinusoidal flicker to be superimposed
on the viewing field, was used to present the stimulus [52].
The goggles comprised two sets of light-emitting diode
(LED) arrays viewed through half-silvered mirrors. The light
intensity generated by the LED arrays was controlled by
a 13Hz sinusoidal voltage waveform, and the nonlinearity
between voltage input and light intensity was less than 0.5%.
2.2.2. Recording. Brain electrical activity was recorded from
64 scalp electrode sites, which included all international
10–20 positions as well as additional sites, located midway
between 10 and 20 locations. The specific locations of the
recording sites have been previously described [53]. The
average potential of both earlobes served as a reference, and
a nose electrode served as ground. Brain electrical activity
was amplified and band-pass filtered (3 dB down at 0.1Hz
and 80Hz) prior to digitization to 16-bit accuracy at a rate of
500Hz.
2.2.3. Signal Processing. The major features of the signal
processing have already been described [53, 54]. Briefly, the
SSVEP was determined from the 13Hz Fourier coeﬃcients
evaluated over 10 stimulus cycles at the stimulus frequency
of 13Hz, thus yielding a temporal resolution of 0.77 sec. The
10-cycle evaluation period is shifted 1 stimulus cycle, and the
coeﬃcients are recalculated for this overlapping period. This
process was continued until the entire period of activity for
each block was analyzed. An identical procedure was applied
to data recorded from all 64 electrodes.
To assess the changes in the SSVEP associated with
diﬀerent components of the cognitive tasks, the following
procedure was employed. For all trials, 10 sec epochs of
SSVEP real and imaginary components commencing 5.0 sec
before the start of the “hold” component were averaged, for
all correct responses. For each subject and each electrode
site, the mean SSVEP amplitude and phase (expressed
as a single complex number) was determined from these
10 sec SSVEP epochs of the control task undertaken in the
postplacebo recording session. This yielded 64 measures
of the mean SSVEP amplitude and phase (one for each
electrode) during the low-demand attention task for each
subject. The 64 amplitude measures were then averaged to
yield a mean SSVEP amplitude for each subject, termed the
normalization factor (NF). Pooled eﬀects were examined
by weighted averaging of the mean SSVEP time series for
object WM trials for all 19 subjects. The weighted averaging
procedure involves normalization of the SSVEP amplitude
time series prior to averaging or pooling across subjects.
This is necessitated by the large intersubject variation in
the SSVEP amplitude [52]. Normalization was achieved by
dividing the mean SSVEP amplitude time series for the WM
trials for each subject by the appropriate NF. The pooled
SSVEP amplitude was then represented as a multiple of the
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normalization factor. Variations in the SSVEP phase were
expressed in terms of latency variations.
2.2.4. Artifact Detection and Compensation. A specific advan-
tage of the SSVEP is its relative noise and artifact insensitivity
[53, 55]. This is a consequence of the fact that signal
power of artifacts such as the electro-oculogram (EOG) and
eye blinks is located primarily at low frequencies and is
negligible above 8Hz [56], while muscle electrical activity
is distributed over a range of frequencies [55]. By contrast,
the SSVEP power is concentrated almost exclusively at the
stimulus frequency, that is, 13Hz and its harmonics [55].
The signal processing technique we have used to extract the
SSVEP is only sensitive to a narrow frequency band centered
on the stimulus frequency and is thus less influenced by
artifact frequency components that diﬀer from the stimulus
frequency. The relative insensitivity of the SSVEP to common
artifacts permits one to relax the rejection criteria for artifact
contamination that are normally employed when evaluating
EEG power spectra. For each subject, the mean SSVEP time
series for the WM task were visually inspected, and any
recording site that was identified as a failure was replaced by
the mean of its 3 nearest neighboring recording sites.
2.2.5. Mapping and Statistical Considerations. Topographic
maps illustrating the diﬀerences in SSVEP latency and ampli-
tude between the pre-GBE and post-GBE conditions were
produced using a spherical spline interpolation procedure
[57]. Statistical probability mapping (SPM; [58]) based on
Hotelling’s T2 measures was based on multiple bivariate
paired T2 test, comparing the SSVEP time series during the
post-GBE session with the equivalent point in time for the
post-placebo session. Those regions of the SPM maps where
T (the square root of Hotelling’s T2) equals 2.88, 3.19, and
3.92 are represented by 3 iso-T contours and correspond
to single comparison P values of 1%, 0.5%, and 0.1%,
respectively.
To account for the multiple comparison undertaken,
the Bonferroni correction was used, based on the spatial
dimensionality of our data [54]. While there are 64 com-
parisons undertaken for each point in time (one for each
electrode), these comparisons are not independent, as the
EEG at neighboring electrodes is highly correlated. The
spatial dimensionality of the data is thus not 64, the number
of scalp recording sites, but a smaller number that takes into
account the correlation between neighboring sites. Spatial
principal components analysis (SPCA) of scalp EEG and
scalp SSVEP suggests that nomore than 5 factors are required
to account for at least 95% of the spatial variance [59, 60]. For
a single set of comparisons based on the 64 scalp recording
sites, this suggests a Bonferroni adjusted P value of 0.05/5,
that is, 1%. If we consider the 2 Hotelling’s T maps presented
in the Results section as 2 independent comparisons, then
an additional application of the Bonferroni correction is
required and the adjusted P value of 1% needs to be divided
by 2 to yield the final adjusted P value of 0.5% as the
experiment-wise probability of 5% for incorrectly rejecting
the null hypothesis.
3. Results and Discussion
3.1. Behavioral Results. We observed an increase in accuracy
from 71.7% in the postplacebo condition to 76.8% in the
post-GBE condition (paired t-test, t = 2.34; df = 18;
P = 0.037). We also observed a non-significant reduction in
reaction time from 1029msec in the postplacebo condition
to 1012msec in the post-GBE condition (paired t-test, t =
0.74; P = 0.46). We observed a modest increase in WM
accuracy immediately after 14-day treatment with GBE. Such
an increase is consistent with other findings that point to
an improvement in WM [10, 15, 24]. While a trend towards
faster reaction times for the WM task was also observed, this
result did not reach statistical significance.
3.2. Brain Electrical Activity
3.2.1. Task-Related Eﬀects. Using the postplacebo condition
to illustrate task-related eﬀects, we noted characteristic
SSVEP changes during the intake and hold components of
the task that have been previously reported [48], specifically,
an SSVEP amplitude reduction during the intake component
of the task and an amplitude increase during the hold
component. SSVEP latency was transiently reduced during
the intake and hold components. The time course of these
changes at midline prefrontal (Fz) and occipital sites (Oz) is
illustrated in Figures 1 and 2, while the SSVEP topography
during the WM or hold component is illustrated in Figure 3.
The hold component is associated with an SSVEP
amplitude increase at parieto-occipital and prefrontal sites
(Figure 3, upper left) and an SSVEP latency reduction at left
temporal and prefrontal sites.
The major task-related SSVEP amplitude change we
observed in the postplacebo condition comprised an increase
at occipitoparietal and frontal sites during the hold or
WM component of the task. These results are consistent
with other observations of a load-dependent increase in the
amplitude of the SSVEP during the hold component of a
WM task [47, 48].
A recent study by Perlstein and colleagues [61] also
reported increased SSVEP amplitude in the right dorsolateral
prefrontal cortex (DLPFC) during the hold component of
a faces WM task. In this case, the amplitude of the SSVEP
at the DLPFC during the hold component was correlated
with task performance. Specifically, larger SSVEP amplitude
was associated with better task performance. Interestingly,
an fMRI study of the same faces WM task [62] also
showed that the largest Bold response was observed in the
DLPFC, the same region responsible for the task-dependent
changes in the SSVEP. It should be noted that such load-
dependent changes in EEG have also been observed in the
alpha frequency range. Specifically, an increased WM load
is associated with increased alpha activity or event-related
synchronization [63, 64].
The major task-related SSVEP latency change we obse-
rved in the postplacebo condition comprised a decrease at
prefrontal and left temporal sites during the hold or WM
component of the task. These results are consistent with
other observations of a load-dependent decrease in SSVEP
latency at prefrontal sites during the hold component of
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Figure 1: (a) SSVEP amplitude at the midline prefrontal electrode
location Fz. SSVEP amplitude is referenced to the mean SSVEP
amplitude averaged over the 10 sec epoch for the post-placebo
control task. Note the increased SSVEP amplitude increase during
the “hold” component compared with the “intake” component. The
GBE related increase in SSVEP amplitude is most prominent during
the hold component. (b) SSVEP latency at the midline prefrontal
electrode location Fz. SSVEP latency is referenced to the mean
SSVEP latency averaged over the 10 sec epoch for the post-placebo
control task. In the post-placebo condition, the SSVEP latency
reduction during the intake component becomes less prominent
during the hold component and reverses to a latency increase at
the end of the hold component. Note the SSVEP latency increase
associated with the GBE.
a WM task [47, 48]. However, the finding of a decrease in
SSVEP latency in the left temporal area is a novel finding,
which was not previously reported in research by Silberstein
and colleagues [48] using a similar WM task.
3.2.2. Ginkgo Eﬀects. SSVEP amplitude and latency topog-
raphy during the middle of the hold component are illus-
trated in Figure 3. The diﬀerences between the postplacebo
(first row) and post-GBE (second row) are illustrated in
the third row. GBE eﬀects that are statistically significant
include increased amplitude at frontal and parietal sites and
increased SSVEP latency at left temporal and left frontal sites.
2 3 4 5 6 7 8 9
SS
V
E
P
am
pl
it
u
de
Intake Hold
Time (s)
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Electrode Oz SSVEP amplitude
post placebo
post ginkgo
(a)
2 3 4 5 6 7 8 9
Intake Hold
Time (s)
1
0
−1
−2
−3
−4
−5
−6
SS
V
E
P
la
te
n
cy
(m
s)
Electrode Oz SSVEP latency
post placebo
post ginkgo
(b)
Figure 2: (a) SSVEP amplitude at the midline occipital electrode
location Oz. SSVEP amplitude is referenced to the mean SSVEP
amplitude averaged over the 10 sec epoch for the post-placebo
control task. Note that greater amplitude increase during the hold
period for the GBE condition. (b) SSVEP latency at the midline
occipital electrode location Oz. SSVEP latency is referenced to the
mean SSVEP amplitude averaged over the 10 sec epoch for the post-
placebo control task. Note the sustained SSVEP latency reduction in
the GBE condition.
3.2.3. Eﬀects of GBE on SSVEP Amplitude. During the hold
component of the task, the GBE-related occipital SSVEP
amplitude increase was more prominent than in the post-
placebo condition. The amplitude increase was also more
prominent in frontal and prefrontal regions for the GBE
condition. While the relationship between this GBE-related
SSVEP amplitude increase and the modest improvement
in performance we observed is speculative, we suggest a
number of observations indicate they are linked. Perlstein
and colleagues [61] examined the relationship between
performance on a face WM task and SSVEP amplitude.
They found that the SSVEP amplitude at prefrontal sites
was positively correlated with performance on the task. A
study by Van Rooy et al. [65] examined the relationship
between IQ and SSVEP amplitude in a spatial WM task.
The authors reported that subjects with high full-scale IQ
6 Evidence-Based Complementary and Alternative Medicine
Amplitude diﬀerence Latency diﬀerence
−0.6
0
0.6
−6.1
0
6.1
(m
s)
post-placebo
post-ginkgo
post-ginkgo–post-placebo
4
0
Hotelling’s T
Figure 3: SSVEP topography 1.6 sec into the hold condition. The first row illustrates the SSVEP amplitude diﬀerence (left column) and
latency diﬀerence (right column) for the post-placebo condition with respect to the mean of the post-placebo control task. The second row
illustrates the same SSVEP diﬀerences for the post-GBE condition while the third row illustrates the diﬀerences between the post-GBE and
post-Placebo conditions. The third row more clearly illustrates the eﬀects of the GBE on SSVEP topography, in particular an increase in
SSVEP latency at left temporal, left frontal, and left prefrontal sites. The single bottom map illustrates the distribution of the square root of
the Hotelling’s T2 parameter with the contours outlining the regions where the T parameter exceeds 2.87, 3.19, and 3.92 corresponding to
single comparison P values of 1%, 0.5%, and 0.1%, respectively.
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(FSIQ) (range 109–130 on WAIS-R) exhibited higher occip-
itoparietal SSVEP amplitude compared with the normal
FSIQ subjects (range 98–108 on WAIS-R) during the hold
component of the spatial WM task. The association of
increased SSVEP amplitude with increased performance level
and measured IQ is thus consistent with our observation of
GBE improving WM performance and SSVEP amplitude.
The reason that an increase in the amplitude of the
SSVEP is associated with increased performance is unclear
although two possible explanations suggest themselves. One
explanation revolves around the notion that the SSVEP
and EEG alpha activity both index a common neural
mechanism and that increased alpha activity (event related
synchronization) and increased SSVEP represent lower levels
of cortical activity or “cortical idling” [66]. In this context,
the increased SSVEP is an index of reduced cortical activity
and is an indication of reduced cognitive eﬀort. The positive
correlation between performance and SSVEP amplitude
observed by Perlstein et al. [61] would thus reflect the
reduced cognitive eﬀort in the high-performance subjects.
Our observation of an increase in SSVEP amplitude could
thus be interpreted as an indirect consequence of GBE’s
enhancement of the eﬃciency of neural systems participating
in the task and thus a reduction in cortical activation.
Alternatively, the increased SSVEP amplitude and alpha
activity may be an indicator of more eﬃcient neural pro-
cesses responsible for holding information on line. We have
previously suggested that corticocortical and corticothalamic
loops may contribute to the generation of spontaneous
and evoked rhythmic activity in the alpha frequency range
[48]. It has also been proposed that these loops may play
a crucial role in holding information “on line” in object
WM tasks. The observation of increased SSVEP and alpha
amplitude with increasing load in a WM task would appear
to be consistent with this proposal [48, 61, 63, 64]. In this
context, the GBE-related increase in SSVEP amplitude is
a consequence of the increased resonant behavior of the
corticocortical loops that is in turn related to the increased
WM capacity. This suggestion is consistent with the eﬀects of
GBE on the ongoing EEG in that GBE has been reported to
increase the amplitude of alpha EEG activity [41, 67].
The mechanisms responsible for the GBE-induced inc-
rease in SSVEP and alpha EEG amplitude is not understood,
but a number of lines of evidence point to the importance
of cholinergic processes. Animal studies briefly reviewed
in the introduction indicate that GBE increases the release
of ACh [29] and also increases the density of muscarinic
cholinergic receptors in the hippocampus [32]. Drugs that
increase the availability of ACh such as cholinesterase
inhibitors (ChEIs) cause an increase in EEG alpha amplitude,
while those that block cortical cholinergic receptors cause
a reduction in EEG alpha activity [68, 69]. Analogous
eﬀects have also been observed for the 13Hz SSVEP.
Nicotine, a nonselective cholinergic agonist, increased the
amplitude of the 13Hz SSVEP in a visual vigilance task,
while Donepezil, a cholinesterase inhibitor, increased the
amplitude of the 13Hz SSVEP component during the hold
component of a spatialWM task [70]. These observations are
consistent with the hypothesis that the GBE-related increase
in SSVEP amplitude was mediated, in part, by cholinergic
processes.
3.2.4. Eﬀects of GBE on SSVEP Latency. In relation to the
eﬀect of GBE on SSVEP latency, the most prominent eﬀect
was that of an increase in SSVEP latency at left temporal,
left prefrontal, and midline frontal sites. By contrast, there
was a tendency for GBE to reduce the midline occipital
SSVEP latency. We have previously suggested that SSVEP
latency changes may index changes in synaptic excitatory
and inhibitory processes in the neural networks generating
the SSVEP. Specifically, SSVEP latency reductions (faster
processing) are a consequence of increased synaptic excita-
tion or reduced inhibition, while SSVEP latency increases
(slower processing) indicate reduced synaptic excitation or
increased inhibition. This interpretation is consistent with
observations that the reaction time in a visual vigilance
task (continuous performance task (CPT)) was correlated
with frontal SSVEP latency [71]. Subsequent studies exam-
ining visual vigilance-related changes in SSVEP latency in
schizophrenia [72] and ADHD [47] have also been consistent
with this suggestion.
Our observation of a GBE-related SSVEP latency increase
at left temporal, frontal, and left prefrontal sites suggests that
GBE is associated with increased levels of synaptic inhibition
during the hold component in these regions. This is con-
sistent with our hypothesis that GBE would be associated
with increased inhibition at temporal and prefrontal sites
and is also consistent with the report of Furey et al. [34,
35] who examined the eﬀects of physostigmine on regional
cerebral blood flow in a faces WM task. The group found
that physostigmine improved performance (reaction time
RT) on the task and that this improvement was correlated
with the magnitude of the rCBF decrease at prefrontal
and left middle temporal gyrus and left superior temporal
sulcus. Our observations of GBE-mediated inhibitory pro-
cesses at left temporal and prefrontal sites together with
PET findings from other laboratories of physostigmine-
mediated reductions in brain activity in left temporal and
prefrontal sites are consistent with the notion that the
cognitive enhancing eﬀects of GBE may in part be mediated
by cholinergic mechanisms. Why the activation of such
cholinergic mechanisms by physostigmine or GBE should be
associated with reductions of left temporal and left prefrontal
rCBF and increased inhibition at these sites is unclear.
One possible explanation that has been suggested is that
increased cholinergic activation of the visual cortex enhances
attentional processes and thus reduces the need to recruit
neural networks in the left temporal and prefrontal cortex
thought to contribute to the retrieval or maintenance of
the visual image [34, 35]. Alternatively, GBE may enhance
WM performance by increasing the cholinergic excitation
of inhibitory cells in the frontal and left temporal cortex.
Such inhibition needs not to represent reduced information
processing by these sites but on the contrary may indi-
cate increased information processing. Cortical GABAergic
interneurons receive strong cholinergic innervation that is
predominantly excitatory [73]. Such GABAergic cells while
only constituting a minority of cortical neurons are thought
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to play a crucial role in neural information processing [74,
75]. Such cells also play a crucial role in the generation of
high-frequency EEG activity or gamma EEG thought to play
an important function in the integration of disparate neural
networks [76]. The role of the GABAergic system in cognitive
information processing has been further emphasized by work
demonstrating that the age-related decline in stimulus selec-
tivity of V1 cells located in the striate cortex was caused by
the decline of GABAergic cell function [77, 78]. The reduced
eﬀectiveness of synaptic inhibitory processes in old age is
also suggested by EEG findings pointing to an age-dependent
reduction in cortical functional independence [79]. This
functional independence is reflected in the dissimilarity of
the EEG across scalp sites. Our observation of GBE-mediated
left temporal and left prefrontal inhibition may thus indicate
increased eﬃciency of the inhibitory neural system and the
consequential enhanced cognitive performance.
In summary, 14-day administration of GBE was associ-
ated with a modest improvement in accuracy in an object
WM task and evidence of increased synaptic inhibition at
left temporal and prefrontal sites during the hold component
of the WM task. We suggest that the improvements in
WM task performance are a consequence of enhanced
synaptic inhibition associated with GBE, possibly operating
via a cholinergic mechanism. These findings provide further
evidence for the eﬃcacy of GBE as a treatment for working
memory deficits in the elderly.
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